Johnson & Johnson (NYSE:JNJ) had its target price hoisted by equities researchers at Stifel Nicolaus from $140.00 to $142.00 in a research report issued to clients and investors on Wednesday. The firm presently has a “hold” rating on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 0.86% from the stock’s current price.

A number of other research analysts have also commented on the stock. UBS AG restated a “buy” rating and set a $148.00 price target (up from $136.00) on shares of Johnson & Johnson in a research report on Wednesday, July 19th. Goldman Sachs Group, Inc. (The) lowered shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and boosted their price target for the company from $125.00 to $130.00 in a research report on Wednesday, September 20th. BMO Capital Markets restated a “buy” rating and set a $145.00 price target on shares of Johnson & Johnson in a research report on Friday, September 1st. Alembic Global Advisors lowered shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research report on Friday, July 21st. Finally, Morgan Stanley boosted their price target on shares of Johnson & Johnson from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Wednesday, July 5th. Five equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $138.35.

Shares of Johnson & Johnson (NYSE:JNJ) opened at 140.79 on Wednesday. The company has a 50 day moving average price of $132.57 and a 200 day moving average price of $130.27. The company has a market capitalization of $377.88 billion, a PE ratio of 23.82 and a beta of 0.78. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $141.12.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. The firm had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.68 EPS. On average, equities research analysts expect that Johnson & Johnson will post $7.18 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/10/18/johnson-johnson-jnj-price-target-raised-to-142-00-at-stifel-nicolaus.html.

In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the sale, the vice president now owns 226,693 shares in the company, valued at $30,993,466.96. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the sale, the vice president now owns 230,342 shares in the company, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Lynch & Associates IN grew its holdings in Johnson & Johnson by 0.9% in the second quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock worth $12,397,000 after purchasing an additional 841 shares during the period. Oakbrook Investments LLC grew its holdings in Johnson & Johnson by 7.4% in the second quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock worth $18,008,000 after purchasing an additional 9,375 shares during the period. Trexquant Investment LP purchased a new stake in Johnson & Johnson in the first quarter worth about $1,731,000. Bollard Group LLC grew its holdings in Johnson & Johnson by 5.0% in the second quarter. Bollard Group LLC now owns 9,551 shares of the company’s stock worth $1,263,000 after purchasing an additional 459 shares during the period. Finally, Adams Diversified Equity Fund Inc. grew its holdings in Johnson & Johnson by 278.0% in the second quarter. Adams Diversified Equity Fund Inc. now owns 241,900 shares of the company’s stock worth $32,001,000 after purchasing an additional 177,900 shares during the period. Institutional investors and hedge funds own 65.90% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.